M.D. Anderson Cancer Center: Neuroendocrine Tumors trials
The registry lists 12 Neuroendocrine Tumors studies with M.D. Anderson Cancer Center as lead sponsor. 1 are open to participants now and 4 have results posted.
Early Phase 1 1Phase 1 2Phase 2 4Phase 3 2No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 PatientsRecruitingNCT03048266
- Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine TumorActive, not recruitingNCT04810091Phase 3Results posted
- Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut OriginCompletedNCT02420691Phase 2Results posted
- Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung CancerCompletedNCT02402920Phase 1Results posted
- Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the CervixTerminatedNCT00626561Phase 2Results posted
- Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid SyndromeWithdrawnNCT04776876Phase 2
- Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid TumorsActive, not recruitingNCT03950609Phase 2
- Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)Status unknownNCT03053999
- Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)Active, not recruitingNCT03043508
- 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine TumorsTerminatedNCT03001349Early Phase 1
- Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant DiseaseWithdrawnNCT01864070Phase 1
- High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine TumorsCompletedNCT00037869Phase 3